SGLT2i vs placebo
Hypoglycaemia · CVD (ASCVD, HF, or both)
SGLT2i showed no clear difference in hypoglycaemia compared with placebo (moderate certainty).
1 finding from 1 review
- Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes onlyOR 0.9 [0.75, 1.07]4 studies · 21232 participantsModerate